Citadel Advisors’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-44,200
| Closed | -$9.76M | – | 13084 |
|
|
2025
Q4 | $9.76M | Sell |
44,200
-13,300
| -23% | -$2.15M | ﹤0.01% | 3286 |
|
|
2025
Q3 | $5.51M | Buy |
57,500
+41,600
| +262% | +$2.65M | ﹤0.01% | 4196 |
|
|
2025
Q2 | $774K | Buy |
15,900
+14,700
| +1,225% | +$353K | ﹤0.01% | 7640 |
|
|
2025
Q1 | $25.8K | Buy |
+1,200
| New | +$26.7K | ﹤0.01% | 12942 |
|
|
2024
Q2 | – | Sell |
-135
| Closed | -$2.48K | – | 14328 |
|
|
2024
Q1 | $2.48K | Buy |
+135
| New | +$1.94K | ﹤0.01% | 14003 |
|
|
2023
Q4 | – | Sell |
-660
| Closed | -$12.4K | – | 14332 |
|
|
2023
Q3 | $12.4K | Sell |
660
-90
| -12% | -$1.77K | ﹤0.01% | 12963 |
|
|
2023
Q2 | $16.9K | Buy |
750
+370
| +97% | +$8.7K | ﹤0.01% | 12870 |
|
|
2023
Q1 | $9.65K | Sell |
380
-1,795
| -83% | -$50.9K | ﹤0.01% | 13580 |
|
|
2022
Q4 | $32.9K | Buy |
2,175
+1,175
| +118% | +$14K | ﹤0.01% | 12625 |
|
|
2022
Q3 | $13K | Buy |
+1,000
| New | +$13.8K | ﹤0.01% | 12196 |
|
|
2022
Q2 | – | Sell |
-1,140
| Closed | -$19K | – | 12962 |
|
|
2022
Q1 | $19K | Buy |
1,140
+460
| +68% | +$7.8K | ﹤0.01% | 13252 |
|
|
2021
Q4 | $17K | Buy |
680
+110
| +19% | +$3.42K | ﹤0.01% | 13602 |
|
|
2021
Q3 | $26K | Buy |
+570
| New | +$21.7K | ﹤0.01% | 13602 |
|
Citadel Advisors's CDTX Position: Q1 2026 in Review
Citadel Advisors sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 269,389 shares — an estimated $59.5M sold.
Citadel Advisors first reported a position in CDTX in Q2 2015 and held it in 17 quarters. The position peaked at $59.5M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Citadel Advisors reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 269,389 Cidara Therapeutics shares in Q1 2026, an estimated $59.5M.
- Citadel Advisors first reported a position in Cidara Therapeutics in Q2 2015 and held it in 17 quarters.
- Citadel Advisors's Cidara Therapeutics position peaked at $59.5M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.